BIOCON.BOBIOCON.BOBSE
Loading
EBITDA Over TimeStrong
Percentile Rank93
3Y CAGR+16.9%
5Y CAGR+14.4%
Studio
Year-over-Year Change

Earnings before interest, taxes, depreciation, and amortization

3Y CAGR
+16.9%/yr
vs +24.0%/yr prior
5Y CAGR
+14.4%/yr
Consistent
Acceleration
-7.1pp
Decelerating
Percentile
P93
Near historical high
vs 5Y Ago
2x
Strong expansion
Streak
1 yr
Consecutive declineStrong
PeriodValueYoY Change
2025$31.24B-4.5%
2024$32.71B+23.1%
2023$26.57B+35.8%
2022$19.56B+18.4%
2021$16.52B+3.6%
2020$15.94B+14.6%
2019$13.92B+68.2%
2018$8.27B-15.7%
2017$9.82B+28.7%
2016$7.63B-